Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

by Zacks Equity Research

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

Here's Why HealthEquity (HQY) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

IceCure Medical (ICCM) delivered earnings and revenue surprises of 14.29% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 54.17% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 56.52% and 21.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Here's Why HealthEquity (HQY) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

HealthEquity (HQY) Gains 25.3% YTD: What's Driving the Rally?

by Zacks Equity Research

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak

by Zacks Equity Research

Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.

Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?

by Zacks Equity Research

Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.

Will UnitedHealth (UNH) Dividend Hike Fail to Excite Investors?

by Zacks Equity Research

UnitedHealth's (UNH) strong financial position supports its shareholder value boosting efforts.

Company News for June 5, 2024

by Zacks Equity Research

Companies In The Article Are:CCL, CNM, HQY, CSCO.

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HealthEquity (HQY) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 21.21% and 3.16%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in kidney care.

Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings

by Zacks Equity Research

Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.

Stay Ahead of the Game With HealthEquity (HQY) Q1 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for HealthEquity (HQY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended April 2024.

Moumi Mondal headshot

Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?

by Moumi Mondal

Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cigna's (CI) Express Scripts Collaborates With CPESN USA

by Zacks Equity Research

Cigna's (CI) Express Scripts collaborates with CPESN USA in a bid to enhance care delivery for hypertension and diabetes patients.